Lamivudine for Solid Tumors
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Solid Tumors
- Interventions
- Drug: LamivudineDrug: PD-L1 Blocker
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 24
- Registration Number
- NCT06494579
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Dupilumab_Metastatic NSCLC
Phase 1
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 21
- Registration Number
- NCT05013450
- Locations
- 🇺🇸
Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, United States
🇺🇸The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath